Atlas Trials

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Clinical trial NCT01721746 · COMPLETED

Trial details

NCT number
NCT01721746
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Unresectable or Metastatic Melanoma
Start date
2012-12-21
Primary completion
2016-02-16
Enrollment
405

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.